Adjuvant Capital logo

Adjuvant Capital

North America, New York, United States, New York

Description

Adjuvant Capital is a life sciences investment firm focused on global health.

Investor Profile

Adjuvant Capital has made 33 investments, with 1 in the past 12 months and 36% as lead.

Stage Focus

  • Series A (30%)
  • Series B (27%)
  • Series C (18%)
  • Series D (9%)
  • Series Unknown (6%)
  • Convertible Note (3%)
  • Series E (3%)
  • Post Ipo Debt (3%)

Country Focus

  • United States (61%)
  • Switzerland (12%)
  • Denmark (9%)
  • United Kingdom (6%)
  • Belgium (6%)
  • China (3%)
  • Austria (3%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Life Science
  • Biopharma
  • Genetics
  • Manufacturing
  • Therapeutics
  • Wellness
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Adjuvant Capital frequently co-invest with?

Wellington Partners
Europe, Bayern, Germany, Munich
Co-Investments: 4
OrbiMed
North America, New York, United States, New York
Co-Investments: 3
LI
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 3
Bossa Invest
South America, Sao Paulo, Brazil, São Paulo
Co-Investments: 3
Johnson & Johnson Innovation – JJDC
North America, Massachusetts, United States, Cambridge
Co-Investments: 3
KdT Ventures
North America, Texas, United States, Austin
Co-Investments: 3
Industrifonden
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 3
GreatPoint Ventures
North America, Michigan, United States, New Haven
Co-Investments: 3
Sanofi Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 4
RI
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 4

Which angels does Adjuvant Capital often collaborate with?

SV
North America, New York, United States, New York
Shared Deals: 1
BP
North America, Florida, United States, St. Petersburg
Shared Deals: 1
SG
North America, Maryland, United States, Bethesda
Shared Deals: 1

What are some of recent deals done by Adjuvant Capital?

Curevo

Bothell, Washington, United States

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

BiopharmaBiotechnologyHealth CareMedical
Series BMar 17, 2025
Amount Raised: $110,000,000
LimmaTech Biologics

Schlieren, Zurich, Switzerland

LimmaTech Biologics AG is a clinical stage biopharmaceutical company.

BiopharmaBiotechnology
Series AFeb 1, 2024
Amount Raised: $3,000,000
Memo Therapeutics

Schlieren, Zurich, Switzerland

Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.

BiotechnologyCollaboration
Series CNov 2, 2023
Amount Raised: $27,587,120
Minervax

Hellerup, Hovedstaden, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

BiotechnologyHealth CareLife ScienceMedicalWellness
Series UnknownOct 11, 2023
Amount Raised: $57,367,288
LimmaTech Biologics

Schlieren, Zurich, Switzerland

LimmaTech Biologics AG is a clinical stage biopharmaceutical company.

BiopharmaBiotechnology
Series AOct 9, 2023
Amount Raised: $36,462,275
Antiva Biosciences

Del Mar, California, United States

Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.

BiotechnologyHealth CareMedical
Series EApr 27, 2023
Amount Raised: $53,000,000
Codagenix

Farmingdale, New York, United States

Codagenix develops live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus.

BiotechnologyGeneticsMedical
Series BFeb 15, 2023
Amount Raised: $25,000,000
InDevR

Boulder, Colorado, United States

InDevR develops and manufactures microarray technologies as well as novel solutions to support the life science industry.

BiotechnologyHealth CareLife ScienceManufacturing
Series BJan 17, 2023
Amount Raised: $9,000,000
Minervax

Hellerup, Hovedstaden, Denmark

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

BiotechnologyHealth CareLife ScienceMedicalWellness
Series CDec 15, 2022
Amount Raised: $23,405,251
Pulmocide

London, England, United Kingdom

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

BiotechnologyHealth CareHealth DiagnosticsMedicalMedical Device
Series CDec 6, 2022
Amount Raised: $52,000,000